contract personnel, solely for cybersecurity purposes. All contract personnel will sign appropriate nondisclosure agreements.

Authority: These investigations are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to section 207.12 of the Commission's rules.

By order of the Commission. Issued: August 9, 2017.

Lisa R. Barton,

Secretary to the Commission.

[FR Doc. 2017-17177 Filed 8-14-17; 8:45 am]

BILLING CODE 7020-02-P

INTERNATIONAL TRADE COMMISSION

[Investigation No. 731-TA-1330 (Final)]

Dioctyl Terephthalate (DOTP) From Korea; Determination

On the basis of the record ¹ developed in the subject investigation, the United States International Trade Commission ("Commission") determines, pursuant to the Tariff Act of 1930 ("the Act"), that an industry in the United States is materially injured by reason of imports of dioctyl terephthalate ("DOTP") from Korea, provided for in subheading 2917.39.20 of the Harmonized Tariff Schedule of the United States, that have been found by the Department of Commerce ("Commerce") to be sold in the United States at less than fair value ("LTFV").²

Background

The Commission, pursuant to section 735(b) of the Act (19 U.S.C. 1673d(b)), instituted this investigation effective June 30, 2016, following receipt of a petition filed with the Commission and Commerce by Eastman Chemical Company, Kingsport, Tennessee. The Commission scheduled the final phase of the investigation following notification of a preliminary determination by Commerce that imports of DOTP from Korea were being sold at LTFV within the meaning of section 733(b) of the Act (19 U.S.C. 1673b(b)). Notice of the scheduling of the final phase of the Commission's investigation and of a public hearing to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the Federal Register of April

12, 2017 (82 FR 17691). The hearing was held in Washington, DC, on June 13, 2017, and all persons who requested the opportunity were permitted to appear in person or by counsel.

The Commission made this determination pursuant to section 735(b) of the Act (19 U.S.C. 1673d(b)). It completed and filed its determination in this investigation on August 9, 2017. The views of the Commission are contained in USITC Publication 4713 (August 2017), entitled *Dioctyl Terephthalate (DOTP) from Korea: Investigation No. 731–TA–1330 (Final).*

By order of the Commission. Issued: August 9, 2017.

Lisa R. Barton.

Secretary to the Commission.

[FR Doc. 2017-17178 Filed 8-14-17; 8:45 am]

BILLING CODE 7020-02-P

JUDICIAL CONFERENCE OF THE UNITED STATES

Meeting of the Judicial Conference Advisory; Committee on Rules of Criminal Procedure

AGENCY: Judicial Conference of the United States, Advisory Committee on Rules of Criminal Procedure.

ACTION: Notice of open meeting.

SUMMARY: The Advisory Committee on Rules of Criminal Procedure will hold a meeting on October 24, 2017. The meeting will be open to public observation but not participation. An agenda and supporting materials will be posted at least 7 days in advance of the meeting at: http://www.uscourts.gov/rules-policies/records-and-archives-rules-committees/agenda-books.

DATES: October 24, 2017.

TIME: 9:00 a.m. to 5:00 p.m.

ADDRESSES: United States District Court for Illinois, Everett McKinley Dirksen United States Courthouse, 219 South Dearborn Street, Chicago, IL 60604.

FOR FURTHER INFORMATION CONTACT:

Rebecca A. Womeldorf, Rules Committee Secretary, Rules Committee Support Office, Administrative Office of the United States Courts, Washington, DC 20544, telephone (202) 502–1820.

Dated: August 8, 2017.

Rebecca A. Womeldorf,

 $Rules\ Committee\ Secretary.$

[FR Doc. 2017-17147 Filed 8-14-17; 8:45 am]

BILLING CODE 2210-55-P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Medical Technology Enterprise Consortium

Notice is hereby given that, on June 23, 2017, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. ("the Act"), Medical Technology Enterprise Consortium ("MTEC") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Appili Theraputics, Inc., Halifax, Nova Scotia, CANADA; BioTime, Inc., Alameda, CA; Chenega Healthcare Services, LLC, San Antonio, TX; Critical Innovations LLC, Venice, CA; Embody LLC, Norfolk, VA; Kansas State University, Manhattan, KS; NovaHep AB, Gothenburg, SWEDEN; Pulmotect, Inc., Houston, TX; QBiotics Limited, Taringa, Queensland, AUSTRALIA; SIMETRI, Inc., Winter Park, FL; SpherIngenics, Inc., Richmond, VA; Spherium Biomed SL, Barcelona, SPAIN; Techulon, Inc., Blacksburg, VA; The Trustees of Columbia University in the City of New York, New York, NY; The University of Texas Health Science Center at Houston, Houston, TX; UT Health San Antonio, San Antonio, TX; and Vapogenix, Inc., Houston, TX, have been added as parties to this venture.

Also, MedPro Technologies, Inc., San Antonio, TX; MetArmor, Inc., Glen Gardner, NJ; Michigan Technological University, Houghton, MI; and Organovo, Inc., San Diego, CA, have withdrawn as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and MTEC intends to file additional written notifications disclosing all changes in membership.

On May 9, 2014, MTEC filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on June 9, 2014 (79 FR 32999).

The last notification was filed with the Department on April 19, 2017. A notice was published in the **Federal**

¹The record is defined in sec. 207.2(f) of the Commission's Rules of Practice and Procedure (19 CFR 207.2(f)).

² Vice Chairman David S. Johanson dissenting.